RU2016141314A3 - - Google Patents

Download PDF

Info

Publication number
RU2016141314A3
RU2016141314A3 RU2016141314A RU2016141314A RU2016141314A3 RU 2016141314 A3 RU2016141314 A3 RU 2016141314A3 RU 2016141314 A RU2016141314 A RU 2016141314A RU 2016141314 A RU2016141314 A RU 2016141314A RU 2016141314 A3 RU2016141314 A3 RU 2016141314A3
Authority
RU
Russia
Application number
RU2016141314A
Other languages
Russian (ru)
Other versions
RU2016141314A (ru
RU2734632C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016141314(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2016141314A publication Critical patent/RU2016141314A/ru
Publication of RU2016141314A3 publication Critical patent/RU2016141314A3/ru
Application granted granted Critical
Publication of RU2734632C2 publication Critical patent/RU2734632C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2016141314A 2010-02-03 2011-02-03 Составы разагилина с пролонгированным высвобождением и их применение RU2734632C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03
US61/301,019 2010-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2012136723A Division RU2607595C2 (ru) 2010-02-03 2011-02-03 Составы разагилина с пролонгированным высвобождением и их применение

Publications (3)

Publication Number Publication Date
RU2016141314A RU2016141314A (ru) 2018-12-14
RU2016141314A3 true RU2016141314A3 (enExample) 2019-12-20
RU2734632C2 RU2734632C2 (ru) 2020-10-21

Family

ID=43896855

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016141314A RU2734632C2 (ru) 2010-02-03 2011-02-03 Составы разагилина с пролонгированным высвобождением и их применение
RU2012136723A RU2607595C2 (ru) 2010-02-03 2011-02-03 Составы разагилина с пролонгированным высвобождением и их применение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012136723A RU2607595C2 (ru) 2010-02-03 2011-02-03 Составы разагилина с пролонгированным высвобождением и их применение

Country Status (25)

Country Link
US (1) US9943489B2 (enExample)
EP (2) EP3517103A1 (enExample)
JP (3) JP6045347B2 (enExample)
KR (1) KR101791715B1 (enExample)
CN (1) CN102791258B (enExample)
AU (1) AU2011212068B2 (enExample)
BR (1) BR112012019374B1 (enExample)
CA (1) CA2789006C (enExample)
CL (1) CL2012002175A1 (enExample)
CY (1) CY1121781T1 (enExample)
DK (1) DK2531181T3 (enExample)
ES (1) ES2733133T3 (enExample)
HU (1) HUE044221T2 (enExample)
IL (1) IL221274A (enExample)
LT (1) LT2531181T (enExample)
MX (1) MX354423B (enExample)
NZ (1) NZ602111A (enExample)
PL (1) PL2531181T3 (enExample)
PT (1) PT2531181T (enExample)
RS (1) RS58988B1 (enExample)
RU (2) RU2734632C2 (enExample)
SG (1) SG183150A1 (enExample)
TR (1) TR201909277T4 (enExample)
WO (1) WO2011095973A1 (enExample)
ZA (1) ZA201206462B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044221T2 (hu) * 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CA2860952C (en) * 2012-01-12 2020-09-15 Pharma Two B Ltd. Fixed dose combination therapy of parkinson's disease
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
BR112015003451A2 (pt) * 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
IN2013MU01782A (enExample) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
HUE054957T2 (hu) * 2014-09-15 2021-10-28 Orphazyme As Arimoklomol készítése
EP4327871B1 (en) 2017-05-19 2025-09-24 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
US11717501B2 (en) * 2018-04-25 2023-08-08 Neurocentria, Inc. Magnesium threonate compositions and uses thereof
MX2021014705A (es) * 2019-05-31 2022-04-06 Denali Therapeutics Inc Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
US20240269083A1 (en) * 2021-05-11 2024-08-15 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN118680910B (zh) * 2024-08-26 2024-12-03 山东齐都药业有限公司 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
CA2107552C (en) 1991-04-04 2001-08-28 William G. Tatton Use of deprenyl to maintain, prevent loss, or recover nerve cell function
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP0966435B1 (en) 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
KR20020008167A (ko) 1999-04-29 2002-01-29 플레믹 크리스티안 잠재적 항정신병제로서의 글리신 분해계 저해제
AU2002355686B2 (en) * 2001-07-04 2007-11-29 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.
NZ565649A (en) * 2005-07-28 2011-03-31 Shire Llc Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
WO2009147681A1 (en) 2008-06-06 2009-12-10 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
US20100008983A1 (en) 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
WO2010007181A2 (en) * 2008-07-18 2010-01-21 Medichem, S.A. New salt forms of an aminoindan derivative
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
HUE044221T2 (hu) * 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik

Also Published As

Publication number Publication date
KR20120130292A (ko) 2012-11-30
PT2531181T (pt) 2019-07-17
NZ602111A (en) 2014-10-31
LT2531181T (lt) 2019-07-10
EP2531181A1 (en) 2012-12-12
EP2531181B1 (en) 2019-04-10
IL221274A (en) 2017-05-29
WO2011095973A1 (en) 2011-08-11
ES2733133T3 (es) 2019-11-27
RS58988B1 (sr) 2019-08-30
CA2789006C (en) 2018-11-27
BR112012019374B1 (pt) 2022-01-11
RU2012136723A (ru) 2014-03-10
TR201909277T4 (tr) 2019-07-22
AU2011212068B2 (en) 2016-08-18
ZA201206462B (en) 2014-02-26
JP2013518870A (ja) 2013-05-23
US9943489B2 (en) 2018-04-17
JP6045347B2 (ja) 2016-12-14
RU2016141314A (ru) 2018-12-14
RU2607595C2 (ru) 2017-01-10
EP3517103A1 (en) 2019-07-31
CL2012002175A1 (es) 2013-01-11
AU2011212068A1 (en) 2012-09-20
KR101791715B1 (ko) 2017-10-30
DK2531181T3 (da) 2019-07-15
CY1121781T1 (el) 2020-07-31
CN102791258B (zh) 2018-05-08
CA2789006A1 (en) 2011-08-11
JP6440662B2 (ja) 2018-12-19
BR112012019374A2 (pt) 2016-05-03
RU2734632C2 (ru) 2020-10-21
CN102791258A (zh) 2012-11-21
JP2019048855A (ja) 2019-03-28
SG183150A1 (en) 2012-09-27
JP2017031189A (ja) 2017-02-09
HUE044221T2 (hu) 2019-10-28
IL221274A0 (en) 2012-10-31
PL2531181T3 (pl) 2019-09-30
US20120301542A1 (en) 2012-11-29
JP6770564B2 (ja) 2020-10-14
MX2012009079A (es) 2012-12-17
MX354423B (es) 2018-03-02

Similar Documents

Publication Publication Date Title
BR112013008959A2 (enExample)
BR112012030039A2 (enExample)
BR112012028408A2 (enExample)
BR112012029986A2 (enExample)
BR112012027808A2 (enExample)
BR112012026492A2 (enExample)
BR112012031500A2 (enExample)
BR112012025307A2 (enExample)
BR112012002126A2 (enExample)
BR112012026946A2 (enExample)
BR112012025482A2 (enExample)
BR112013006400A2 (enExample)
BR112012031826A2 (enExample)
BR112012025577A2 (enExample)
BR112012028186A2 (enExample)
BR112012016456A2 (enExample)
BR112012027015A2 (enExample)
BR112012025308A2 (enExample)
RU2016141314A3 (enExample)
BR112013010949A2 (enExample)
BR112012027945A2 (enExample)
BR112013003284A2 (enExample)
BR112012026403A2 (enExample)
BR112013002646A2 (enExample)
BR112012022788A2 (enExample)